Clinical Trials Logo

Sclerosis clinical trials

View clinical trials related to Sclerosis.

Filter by:

NCT ID: NCT02665221 Terminated - Multiple Sclerosis Clinical Trials

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

Start date: July 2015
Phase: Phase 4
Study type: Interventional

The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength Cream compared to no topical treatment of injection site erythema after PLEGRIDY injection.

NCT ID: NCT02654340 Terminated - Clinical trials for Lymphangioleiomyomatosis

Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)

TuScCom
Start date: August 1, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s

NCT ID: NCT02644083 Terminated - Multiple Sclerosis Clinical Trials

Tecfidera and MRI for Brain Energy in MS

Start date: February 2016
Phase:
Study type: Observational

The primary objective of this study is to test the hypothesis that DMF can improve mitochondrial function in the brain of people with MS. The investigators will assess mitochondrial function in the cerebral grey matter by measuring PCr and ATP by 31P magnetic resonance spectroscopy (MRS) and NAA in NAWM by 1H MRS.

NCT ID: NCT02642146 Terminated - Systemic Sclerosis Clinical Trials

Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study

Start date: January 2015
Phase:
Study type: Observational [Patient Registry]

This study evaluates the efficacy and safety of routine medical treatments of digital ulcers in patients with systemic sclerosis in a prospective cohort study.

NCT ID: NCT02609607 Terminated - Multiple Sclerosis Clinical Trials

Treating Anorectal Dysfunction in MS

Start date: June 2016
Phase: Phase 2
Study type: Interventional

The investigators seek to test whether incorporating the scheduled dosing of a bisacodyl 10 mg rectal suppository every other day improves bowel-related symptoms in patients with multiple sclerosis. Patients will be randomized to receive either a placebo suppository or bisacodyl suppository dosed every other day for 4 weeks.

NCT ID: NCT02606630 Terminated - Multiple Sclerosis Clinical Trials

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Start date: October 2015
Phase: Phase 1
Study type: Interventional

This open-label positron emission tomography (PET) study is designed to determine the effect of ABT-555 on translocator protein expression level in participants with relapsing forms of multiple sclerosis.

NCT ID: NCT02580669 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis

VASOSEP
Start date: June 16, 2014
Phase: N/A
Study type: Interventional

The goal of this study is to show pattern differences of vasoreactivity and connectivity between Progressive Multiple Sclerosis and Relapsing Remitting Multiple Sclerosis, by the use of methods of advanced brain MRIs and the Diffusion Tensor Imaging , and correlate these differences with Clinical disability and cognitive disorder results.

NCT ID: NCT02528071 Terminated - Clinical trials for ALS (Amyotrophic Lateral Sclerosis)

Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis

SLA
Start date: September 29, 2014
Phase:
Study type: Observational

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure. The occurrence of respiratory failure is associated with morbidity and an increased mortality. To date, respiratory muscle weakness is predicted from the reduction of vital capacity, maximal inspiratory force, nocturnal symptoms and hypercapnia. Even taken together, the predictive value of these indices is low. The investigators hypothesize that an endurance test of diaphragmatic work would be more sensitive to respiratory muscle involvement than maximal respiratory force. Consequently, the investigators assessed diaphragmatic performance through an isocapnic hyperventilation test (IHT) in patients at the onset of ALS and, then regularly up to the occurrence of respiratory failure. The investigators make the hypothesis that IHT will be altered earlier than maximal inspiratory force

NCT ID: NCT02525367 Terminated - Multiple Sclerosis Clinical Trials

Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy

Start date: March 2016
Phase: N/A
Study type: Interventional

In Parkinson's disease, Multiple Sclerosis and depressed patients treated with electroconvulsive therapy, cognitive dysfunction is prevalent. However, treatment of these dysfunctions is in its infancy. The purpose of this study is 1) to assess the feasibility of a randomized controlled trial using an online computerized intervention for training cognitive abilities in the three patient groups and 2) to estimate the effect of the online training on objectively and subjectively measured cognitive functions. The investigators hypothesize that patients using online cognitive training will improve more on cognitive functions, as compared to patients using an active control condition.

NCT ID: NCT02466074 Terminated - Multiple Sclerosis Clinical Trials

Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis

perfuseMS
Start date: August 17, 2016
Phase: Phase 2
Study type: Interventional

This study will evaluate how improved cerebral blood flow affects the way in which newly formed MS lesions evolve and whether tissue repair is improved. Patients with multiple sclerosis (MS) will be treated with acetazolamide in daily divided doses and obtain MRI to determine how much and in which regions of the brain cerebral perfusion improves as well as the extent to which tissue integrity is improved in these areas.